CGON Stock Up 60.8% in Six Months: Here's What You Need to Know
CG Oncology stock surges as early phase III data, strong bladder cancer results and a $900M cash cushion fuel rising investor confidence.
| Ticker |
CGON
|
| CIK | 0001991792 |
| SIC | 2836 |
| Sector | Manufacturing |
| Industry Category | Pharmaceutical Products |
| Industry Group | Biological Products, Except Diagnostic Substances |
| Address | 400 SPECTRUM CENTER DRIVE, SUITE 2040, IRVINE, CA, 92618 |
| Website | cgoncology.com |
| Phone | (949) 419-6203 |
| CEO | Arthur Kuan |
| Employees | N/A |
Our team will help you customize a package that meets the needs of your business.
Request a Consultation|
Standardized FinancialsdocsIntrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals. For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards. Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics: |
|||||||||||||||||||||
|
Income Statement
|
Balance Sheet
|
||||||||||||||||||||
|
Cash Flow Statement
|
Calculations
|
||||||||||||||||||||
|
Latest NewsdocsIntrinio provides up-to-date news articles on every US company from various sources. Here are several examples: |
CGON Stock Up 60.8% in Six Months: Here's What You Need to KnowCG Oncology stock surges as early phase III data, strong bladder cancer results and a $900M cash cushion fuel rising investor confidence. As Terns Stock Soars 1,400%, What Does One Fund's $5.2 Million Sale Signal to Investors?This clinical-stage biotech develops therapies for NASH and obesity, advancing a pipeline of proprietary small-molecule drug candidates. This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should KnowThis clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients, targeting unmet needs in oncology treatment. Is CG Oncology (CGON) Pricing Reflect Its Recent 131% Surge And Cancer Breakthrough HopesIf you are wondering whether CG Oncology's recent share price puts it on sale or already prices in a lot of optimism, you are asking the right question for this stock. Over the past week the share price return was 3.9%, over the last month it was 20.1%, year to date it was 53.8%, and over the past year it was 131.3%, which naturally raises questions about what is already baked into the current US$64.29 price. Recent news coverage has focused on CG Oncology as a cancer focused biotech name,... CG Oncology Conference: Credo Posts 75.5% CR in BOND-003, BLA Filing Targeted for 2026Executives from CG Oncology (NASDAQ:CGON) outlined clinical results, ongoing trials, and launch preparations for its investigational intravesical therapy cretostimogene (referred to as “Credo”) during a recent company event, emphasizing response durability in high-risk non–muscle invasive bladder ca |